13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
46 檔
45.0%
As reported in its official Q1 2026 Form 13F filing, Vivo Capital, LLC's tracked investment portfolio stood at $1.1B with 46 total positions.
In Q1 2026, Vivo Capital, LLC adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 9 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including ERAS, PRAX, 430) accounted for 45.0% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | Stock-Other | 16.34% | -9.44% | +31.04% | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 9.08% | -0.79% | +3.04% | |
| 3 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 5.85% | -5.85% | EXIT | |
| 4 | TRVI | Trevi Therapeutics Inc | Stock-Other | 5.05% | +3.63% | — | |
| 5 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 4.63% | -1.87% | +8.37% | |
| 6 | CMPX | Compass Therapeutics Inc | Stock-Other | 4.20% | -2.65% | — | |
| 7 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.75% | +0.19% | — | |
| 8 | SABS | Sab Biotherapeutics Inc | Stock-Other | 3.64% | -1.04% | — | |
| 9 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 3.41% | +0.42% | +25.56% | |
| 10 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 3.38% | +0.19% | +11.08% | |
| 11 | SVA | Sinovac Biotech Ltd. | Stock-Other | 3.17% | +0.32% | — | |
| 12 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.47% | +0.68% | — | |
| 13 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.35% | +0.81% | -40.44% | |
| 14 | ABVX | Abivax Sa-adr | Stock-Other | 2.22% | +2.83% | -33.33% | |
| 15 | NERV | Minerva Neurosciences Inc | Stock-Other | 2.17% | +0.03% | — | |
| 16 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 2.08% | +1.15% | -25.00% | |
| 17 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.95% | -0.12% | -12.73% | |
| 18 | ANRO | Alto Neuroscience Inc | Stock-Other | 1.94% | +0.97% | — | |
| 19 | FTH | Faeth Therapeutics Inc | Stock-Other | 1.89% | -0.24% | — | |
| 20 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.70% | +3.64% | — | |
| 21 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.64% | +0.73% | — | |
| 22 | MANE | Veradermics Inc | Stock-Other | 1.57% | -1.57% | EXIT | |
| 23 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 1.56% | +0.13% | — | |
| 24 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.55% | +0.94% | — | |
| 25 | DSGN | Design Therapeutics Inc | Stock-Other | 1.43% | +0.70% | — | |
| 26 | COGT | Cogent Biosciences Inc | Stock-Other | 1.35% | -1.35% | EXIT | |
| 27 | GERN | Geron CORP | Stock-Other | 1.07% | -0.06% | -68.15% | |
| 28 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.98% | -0.74% | — | |
| 29 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.90% | +0.49% | — | |
| 30 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.83% | -0.06% | — | |
| 31 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.82% | -0.82% | EXIT | |
| 32 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 0.81% | — | — | |
| 33 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.66% | +0.14% | — | |
| 34 | SRZN | Surrozen Inc | Stock-Other | 0.63% | -0.01% | — | |
| 35 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.53% | +0.07% | — | |
| 36 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.41% | +0.36% | — | |
| 37 | MSLE | Satellos Bioscience Inc | Stock-Other | 0.38% | +0.20% | — | |
| 38 | PEPG | Pepgen Inc | Stock-Other | 0.34% | +0.04% | — | |
| 39 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.28% | -0.01% | — | |
| 40 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.28% | +3.04% | — | |
| 41 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.27% | -0.27% | EXIT | |
| 42 | TIL | Instil Bio Inc | Stock-Other | 0.20% | +0.01% | — | |
| 43 | KTTA | Pasithea Therapeutics CORP | Stock-Other | 0.13% | -0.11% | — | |
| 44 | CMPS | Compass Pathways PLC | Stock-Other | 0.09% | -0.09% | EXIT | |
| 45 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.02% | +0.01% | — | |
| 46 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | +14.1% | +31.04% | Add |
| 2 | PRAX | Praxis Precision Medicines I | +2.8% | +3.04% | Add |
| 3 | TNGX | Tango Therapeutics Inc | +2.5% | — | Unchanged |
| 4 | CRVS | Corvus Pharmaceuticals Inc | +2.3% | +25.56% | Add |
| 5 | DBVT | Dbv Technologies Sa-spon Adr | +1.6% | +8.37% | Add |
| 6 | DNTH | Dianthus Therapeutics Inc | +1.5% | — | Unchanged |
| 7 | NERV | Minerva Neurosciences Inc | +1% | — | Unchanged |
| 8 | TRVI | Trevi Therapeutics Inc | +0.9% | — | Unchanged |
| 9 | CMPX | Compass Therapeutics Inc | +0.9% | — | Unchanged |
| 10 | SABS | Sab Biotherapeutics Inc | +0.9% | — | Unchanged |
| 11 | DRUG | Bright Minds Biosciences Inc | +0.9% | +11.08% | Add |
| 12 | ORIC | Oric Pharmaceuticals Inc | +0.8% | -12.73% | Trim |
| 13 | ANRO | Alto Neuroscience Inc | +0.8% | — | Unchanged |
| 14 | MLTX | Moonlake Immunotherapeutics | +0.7% | — | Unchanged |
| 15 | SVA | Sinovac Biotech Ltd. | +0.7% | — | Unchanged |
| 16 | LBRX | Lb Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 17 | DSGN | Design Therapeutics Inc | +0.5% | — | Unchanged |
| 18 | ACRS | Aclaris Therapeutics Inc | +0.4% | -25.00% | Trim |
| 19 | UNCY | Unicycive Therapeutics Inc | +0.3% | — | Unchanged |
| 20 | SRZN | Surrozen Inc | +0.3% | — | Unchanged |
| 21 | EPRX | Eupraxia Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 22 | TENX | Tenax Therapeutics Inc | +0.1% | — | Unchanged |
| 23 | MNPR | Monopar Therapeutics Inc | 0% | — | Unchanged |
| 24 | DTIL | Precision Biosciences Inc | — | — | Unchanged |
| 25 | TIL | Instil Bio Inc | 0% | — | Unchanged |
| 26 | BOLT | Bolt Biotherapeutics Inc | 0% | — | Unchanged |
| 27 | SERA | Sera Prognostics Inc-a | 0% | — | Unchanged |
| 28 | KTTA | Pasithea Therapeutics CORP | -0.1% | — | Unchanged |
| 29 | CAMP | Camp4 Therapeutics CORP | -0.1% | — | Unchanged |
| 30 | OLMA | Olema Pharmaceuticals Inc | -0.3% | — | Unchanged |
| 31 | PEPG | Pepgen Inc | -0.6% | — | Unchanged |
| 32 | ABVX | Abivax Sa-adr | -0.9% | -33.33% | Trim |
| 33 | DYN | Dyne Therapeutics Inc | -1% | -40.44% | Trim |
| 34 | GERN | Geron CORP | -1.3% | -68.15% | Trim |
| 35 | VRDN | Viridian Therapeutics Inc | -1.7% | -83.08% | Trim |
| 36 | SLNOEUR | Soleno Therapeutics Inc | -1.9% | -67.05% | Trim |
| 37 | COGT | Cogent Biosciences Inc | -4.2% | -82.40% | Trim |
| 38 | 430 | Terns Pharmaceuticals Inc | -8.1% | -75.04% | Trim |
| 39 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 40 | ✓ | Avadel Pharmaceuticals PLC ADR | — | EXIT | Sold out |
| 41 | ZBIO | Zenas Biopharma Inc | — | EXIT | Sold out |
| 42 | FTH | Faeth Therapeutics Inc | — | NEW | New buy |
| 43 | AVBP | Arrivent Biopharma Inc | — | NEW | New buy |
| 44 | MANE | Veradermics Inc | — | NEW | New buy |
| 45 | CTMX | Cytomx Therapeutics Inc | — | EXIT | Sold out |
| 46 | ANTX | An2 Therapeutics Inc | — | NEW | New buy |
| 47 | ABEO | Abeona Therapeutics Inc | — | EXIT | Sold out |
| 48 | VSTM | Verastem Inc | — | EXIT | Sold out |
| 49 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| 50 | SLN | Silence Therapeutics Plc-adr | — | EXIT | Sold out |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 46 disclosed positions in Q1 2026.
During Q1 2026, Vivo Capital, LLC's top holdings by market value included ERAS (16.3%)、PRAX (9.1%)、430 (5.8%). The largest single position, ERAS, represented 16.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
FTH
市值: $22.8M
Top Position Liquidated / Trimmed
CDTX
前期市值: $211.3M
In Q1 2026, Vivo Capital, LLC made 31 total portfolio adjustments, initiating 8 new buys, adding to 5 positions, trimming 9 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.